Assessment of BIV1-CovIran inactivated vaccine-elicited neutralizing antibody against the emerging SARS-CoV-2 variants of concern

被引:8
作者
Salehi, Mohammadreza [1 ]
Hosseini, Hamed [2 ]
Jamshidi, Hamid Reza [3 ]
Jalili, Hasan [4 ]
Tabarsi, Payam [5 ]
Mohraz, Minoo [6 ]
Karimi, Hesam [7 ]
Lotfinia, Majid [8 ]
Aalizadeh, Reza [9 ]
Mohammadi, Mehrdad [10 ]
Ramazi, Shahin [11 ]
Abdoli, Asghar [7 ,12 ]
机构
[1] Univ Tehran Med Sci, Infect Dis Dept, Tehran, Iran
[2] Univ Tehran Med Sci, Ctr Res & Training Skin Dis & Leprosy, Tehran, Iran
[3] Shahid Beheshti Univ Med Sci, Dept Pharmacol, Tehran, Iran
[4] Univ Tehran, Fac New Sci & Technol, Dept Life Sci Engn, Tehran, Iran
[5] Shahid Beheshti Univ Med Sci, Clin TB & Epidemiol Res Ctr, Dept Infect Dis, Tehran, Iran
[6] Univ Tehran Med Sci, Iranian Res Ctr HIV Aids, Tehran, Iran
[7] Pasteur Inst Iran, Dept Hepatitis & AIDS, Tehran, Iran
[8] Kashan Univ Med Sci, Physiol Res Ctr, Kashan, Iran
[9] Tarbiat Modares Univ, Fac Biol Sci, Dept Biochem, Tehran, Iran
[10] Kashan Univ Med Sci, Sch Med, Dept Microbiol & Immunol, Kashan, Iran
[11] Tarbiat Modares Univ, Fac Biol Sci, Dept Biophys, Tehran, Iran
[12] Vaccine Unit, Amirabad Virol Lab, Tehran, Iran
关键词
BIV1-CovIran vaccine; COVID-19; vaccine; SARS-CoV-2; variants; Virus neutralization test;
D O I
10.1016/j.cmi.2022.02.030
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: The BIV1-CovIran vaccine is highly effective against COVID-19. The neutralizing potency of all SARS-CoV-2 vaccines seems to be decreased against variants of concern. We assessed the sensitivity of the Alpha (B.1.1.7), Beta (B.1.351), and Delta (B.1.617.2) variants to neutralizing antibodies (NAbs) present in sera from individuals who had received the BIV1-CovIran candidate vaccine compared with an original Wuhan-related strain. Methods: The ability of vaccine serum to neutralize the variants was measured using the conventional virus neutralization test. The correlation of spike (S) protein antibody and anti-receptor binding domain with neutralizing activity was investigated. Results: The current study demonstrated that 29 of 32 (90.6%; 95% CI: 75.0-98.0) of the vaccinees developed NAbs against a Wuhan-related strain. It is noteworthy that 28 (87.50%) and 24 of 32 (75%) of the recipients were able to produce NAbs against Alpha, Beta, and Delta variants, respectively. Serum virus-neutralizing titres for different SARS-CoV-2 strains were weakly correlated with anti-receptor binding domain antibodies (Spearman r = 36-42, p < 0.05), but not S-binding antibodies (p > 0.05). Discussion: Although there was a reduction in neutralization titres against the Alpha, Beta, and Delta variants compared with the Wuhan strain, BIV1-CovIran still exhibited potent neutralizing activity against the SARS-CoV-2 variants of concern. (C) 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:882.e1 / 882.e7
页数:7
相关论文
共 50 条
  • [21] A receptor-binding domain-based nanoparticle vaccine elicits durable neutralizing antibody responses against SARS-CoV-2 and variants of concern
    Lee, I-Jung
    Lan, Yu-Hua
    Wu, Ping-Yi
    Wu, Yan-Wei
    Chen, Yu-Hung
    Tseng, Sheng-Che
    Kuo, Tzu-Jiun
    Sun, Cheng-Pu
    Jan, Jia-Tsrong
    Ma, Hsiu-Hua
    Liao, Chun-Che
    Liang, Jian-Jong
    Ko, Hui-Ying
    Chang, Chih-Shin
    Liu, Wen-Chun
    Ko, Yi-An
    Chen, Yen-Hui
    Sie, Zong-Lin
    Tsung, Szu-, I
    Lin, Yi-Ling
    Wang, I-Hsuan
    Tao, Mi-Hua
    EMERGING MICROBES & INFECTIONS, 2023, 12 (01)
  • [22] SARS-CoV-2 bivalent mRNA vaccine with broad protection against variants of concern
    Ma, Qinhai
    Li, Man
    Ma, Lin
    Zhang, Caroline
    Zhang, Hong
    Zhong, Huiling
    Wen, Jian
    Wang, Yongsheng
    Yan, Zewei
    Xiong, Wei
    Wu, Linping
    Guo, Jianmin
    Yang, Wei
    Yang, Zifeng
    Zhang, Biliang
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [23] Safety and immunogenicity of an inactivated virus particle vaccine for SARS-CoV-2, BIV1-CovIran: findings from double-blind, randomised, placebo-controlled, phase I and II clinical trials among healthy adults
    Mohraz, Minoo
    Salehi, Mohammadreza
    Tabarsi, Payam
    Abbasi-Kangevari, Mohsen
    Ghamari, Seyyed-Hadi
    Ghasemi, Erfan
    Pouya, Maryam Amini
    Rezaei, Negar
    Ahmadi, Naser
    Heidari, Kazem
    Malekpour, Mohammad-Reza
    Nasiri, Mojtaba
    Amirzargar, Ali Akbar
    Moghaddam, Sahar Saeedi
    Larijani, Bagher
    Hosseini, Hamed
    BMJ OPEN, 2022, 12 (04):
  • [24] Association of selenium profile with neutralizing antibody response to inactivated SARS-CoV-2 vaccination
    Gao, Sikang
    Ren, Na
    Sun, Taoping
    Nie, Qi
    Liu, Sitian
    Geng, Xuyang
    Deng, Yao
    Lin, Zefang
    Liu, Yu
    Zhou, Li
    JOURNAL OF TRACE ELEMENTS IN MEDICINE AND BIOLOGY, 2023, 80
  • [25] Prediction of long-term kinetics of vaccine-elicited neutralizing antibody and time-varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint
    Chen, Xinhua
    Wang, Wei
    Chen, Xinghui
    Wu, Qianhui
    Sun, Ruijia
    Ge, Shijia
    Zheng, Nan
    Lu, Wanying
    Yang, Juan
    Rodewald, Lance
    Yu, Hongjie
    BMC MEDICINE, 2022, 20 (01)
  • [26] Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern
    Dupont, Liane
    Snell, Luke B.
    Graham, Carl
    Seow, Jeffrey
    Merrick, Blair
    Lechmere, Thomas
    Maguire, Thomas J. A.
    Hallett, Sadie R.
    Pickering, Suzanne
    Charalampous, Themoula
    Alcolea-Medina, Adela
    Huettner, Isabella
    Jimenez-Guardeno, Jose M.
    Acors, Sam
    Almeida, Nathalia
    Cox, Daniel
    Dickenson, Ruth E.
    Galao, Rui Pedro
    Kouphou, Neophytos
    Lista, Marie Jose
    Ortega-Prieto, Ana Maria
    Wilson, Harry
    Winstone, Helena
    Fairhead, Cassandra
    Su, Jia Zhe
    Nebbia, Gaia
    Batra, Rahul
    Neil, Stuart
    Shankar-Hari, Manu
    Edgeworth, Jonathan D.
    Malim, Michael H.
    Doores, Katie J.
    NATURE MICROBIOLOGY, 2021, 6 (11) : 1433 - U204
  • [27] Emerging SARS-CoV-2 Variants of Concern (VOCs): An Impending Global Crisis
    Thye, Angel Yun-Kuan
    Law, Jodi Woan-Fei
    Pusparajah, Priyia
    Letchumanan, Vengadesh
    Chan, Kok-Gan
    Lee, Learn-Han
    BIOMEDICINES, 2021, 9 (10)
  • [28] Identification of SARS-CoV-2 variants of concern in vaccine-breakthrough infections
    Abdalhamid, Baha
    Donahue, Matthew
    Kamal-Ahmed, Ishrat
    Strand, Kyle
    Mitchell, Elizabeth
    Iwen, Peter C.
    JOURNAL OF INFECTION IN DEVELOPING COUNTRIES, 2022, 16 (04): : 580 - 582
  • [29] Diverse vaccine platforms safeguarding against SARS-CoV-2 and its variants
    Chatterjee, Bhaswati
    Thakur, Suman S.
    EXPERT REVIEW OF VACCINES, 2022, 21 (01) : 47 - 67
  • [30] Vaccine-elicited immune pressure and SARS-CoV-2 mutational dynamics in breakthrough infections
    Kumar, Sarwareddy Kartik
    Sathrasala, Srinivas
    Krishna, Jandhyala Sai
    Sreekanth, Patnam
    Singh, Anula Divyash
    Ratnamani, M. S.
    Kalal, Iravathy Goud
    Tallapaka, Karthik Bharadwaj
    Kumar, Gajjela Praveen
    Sasidhar, Manda Venkata
    Kuragayala, Swarna Deepak
    GENE REPORTS, 2024, 35